



# ***IN VITRO* MODELS TO PREDICT PHOTOTOXICITY: STRATEGIES BASED ON THE CELLULAR MECHANISMS INVOLVED**

Dra. Adriana S. Maddaleno

Secció Fisiologia

Facultat de Farmàcia i CCAA

Seminari de recerca 10/04/24



UNIVERSITAT DE  
BARCELONA

Facultat de Farmàcia  
i Ciències de l'Alimentació



# 1. Introduction

- Solar light: Benefits and pathogenesis
- Phototoxicity
  - Photoirritation
  - Photoallergy
- Models in phototoxicity

# 2. Methodology

# 3. Results and Conclusions


# 4. More in vitro models in phototoxicity

# PRESENTATION



Secció de Fisiologia.  
Departament de  
Bioquímica i Fisiologia

**Cellular  
Response to  
Xenobiotics  
(CEREX)**




**SGR**  
Bioquímica  
Integrativa

## Research

- Evaluation of the antioxidant power of products of natural origin.
- Genotoxicity studies adapted to the evaluation of the potential photoprotective effects of products of natural origin.
- Nanotoxicology in vitro
- **Development of in vitro techniques for studies of (photo) irritation and (photo) dermal sensitization.**



# 1. INTRODUCTION



# SOLAR LIGHT BENEFITS

Vitamin D

Regulates body  
temperature

Fights Stress  
and Insomnia



Maintains  
Circadian Rhythm

Serotonin

Melatonin

Improves  
Mood

# SOLAR LIGHT PATHOGENESIS



Skin Cancer



Hyperpigmentation



Redness




Photoaging




**Photosensitivity**

(Caused by photoactive molecules in skin)


Driffey 2017, Krueger and N. Elbuluk 2021, Nou et al. 2015




Solar Radiation Spectrum



UV penetration into the layers of the skin.  
Pérez-Sánchez et al. 2018



# PHOTOTOXICITY: PHOTOIRRITATION (PI)




Calitxo et al. 2016

- Common, dose-dependent
- Often exaggerated sunburn, erythema
- Histopathology: Necrotic keratinocytes, minimal inflammation
- Local manifestation




# PHOTOTOXICITY: PHOTOALLERGY (PA)

- Uncommon, not dose-dependent
- Usually dermatitis
- Histopathology: Spongiotic dermatitis with eosinophils
- Can extend beyond



# PHOTOPATCH TEST



**Table 3** Interpretation of photopatch test results

Reading 1		Reading 2 or 3		Test results	Interpretation of positive reactions
No UV	UVA	No UV	UVA		
–	++ <sup>a</sup>	–	–	Immediate reaction	Photocontact urticaria
–	–	–	+ to +++	Positive photopatch test	Photoallergy or phototoxicity
+	+	++	++	Positive patch test	Contact allergy
+	+	+	++ or +++	Photoaggravated patch test	Photo-augmented contact allergy/or contact allergy+photoallergy
++	++	++	– or +	Photo-inhibition <sup>b</sup>	

<sup>a</sup>Immediate urticarial reaction after irradiation. Do not consider faint erythema occasionally observed with chemicals with more phototoxic potential

<sup>b</sup>The meaning of this type of reaction is not completely understood

Chong et al. 2017

# PHOTOTOXICITY: PRECLINICAL STUDIES IN RESEARCH

## Animal methods



### In vivo

- Photo-local lymph node assay

## Non-animal methods



### In silico

- QSAR
- Toxtree



### In chemico

- TG 101: UV-VIS absorption spectrum
- TG 495: ROS Assay for photoreactivity



### In vitro

- TG 432: In vitro 3T3 NRU phototoxicity test
- TG 498: RHE phototoxicity test method

# Why are *in vitro* models important?

## 3R Principle

- Replacement
- Reduction
- Refinement

## Regulation and ethical guidelines

- REACH, Pharmaceuticals...  
Promotion alternatives
- Banning of animal testing for cosmetics  
(EU & Other countries)



- No *In vitro* models available to discriminate PI & PA
- Proposes to identify PA based on the AOP of skin sensitisation






Figure 3. Flow diagram of the pathways associated with skin sensitisation.





Schematic overview of the of the proposed Adverse Outcome Pathway (AOP) key events (KEs) of skin photoallergy.

Ávila et al. 2023




## MAIN GOAL OF THE PROJECT







Identify markers to discriminate between PI & PA





## 2. METHODOLOGY







Layers of the skin. Sarabahi, S. and Bajaj, S.P. (2010) .

## Development of an *in vitro* model using keratinocytes


Epidermis: **Keratinocytes**, Melanocytes, Langerhan cells...




Chlorpromazine HCl (CPZ)  
**PI/PA**



8-methoxypsoralen (8-MOP)  
**PI**




Benzophenone (BZ-F)  
**PA**




P-Phenyldiamine (PPD)  
**A**

# Experimental design

- Protocol based on OECD TG 432
- Keratinocytes instead of fibroblasts (BALB/c 3T3)



Human keratinocytes (HaCaT)



## Cellular viability


- IC50 Dark
- IC50 UVA

↓  
PIF

**CV80**


↓  
Next study

PIF	Classification
<2	Non-phototoxic
2-5	Probable phototoxic
>5	Phototoxic




Human  
keratinocytes  
(HaCaT)

24h,  
5%  
CO<sub>2</sub>,  
37°C

  
Incubation  
with  
compounds\*  
in PBS  
\*[ ] > CV80

1h,  
5%  
CO<sub>2</sub>,  
37°C


  
UVA  
irradiation  
4 J/cm<sup>2</sup>


24h,  
5%  
CO<sub>2</sub>,  
37°C

Supernatants  
collection


## Semi-Quantitative study

- Anti-inflammatory cytokines
- MMPS







### 3. RESULTS AND CONCLUSIONS



## CPZ (PI/PA)





**Figure 1.** Cell viability of keratinocytes obtained through MTT and NRU assays, treated with different concentrations of CPZ exposed to 4 J/cm<sup>2</sup>. The percentage of viable cells was calculated relative to cells not treated with CPZ (darkness and UVA control). The results are expressed as the mean ± standard deviation of at least 3 replicates.

	MTT	NRU
IC50 DARK	46.3	34.2
IC50 UVA	2.1	8.7
PIF	21.6	3.9




## 8-MOP (PI)



**Figure 2.** Cell viability of keratinocytes obtained through MTT and NRU assays, treated with different concentrations of 8-MOP exposed to 4 J/cm<sup>2</sup>. The percentage of viable cells was calculated relative to cells not treated with 8-MOP (darkness and UVA control). The results are expressed as the mean ± standard deviation of at least 3 replicates.

	MTT	NRU
<b>IC50 DARK</b>	>2.5	>2.5
<b>IC50 UVA</b>	0.12	1.5
<b>PIF</b>	>20.5	>1.7


## BZ-F (PA)





**Figure 3.** Cell viability of keratinocytes obtained through MTT and NRU assays, treated with different concentrations of BZ-F exposed to 4 J/cm<sup>2</sup>. The percentage of viable cells was calculated relative to cells not treated with BZ-F (darkness and UVA control). The results are expressed as the mean ± standard deviation of at least 3 replicates.

	MTT	NRU
<b>IC50 DARK</b>	458.1	684.6
<b>IC50 UVA</b>	13.6	42.8
<b>PIF</b>	33.6	16.0

## PPD (A)





**Figure 4.** Cell viability of keratinocytes obtained through MTT and NRU assays, treated with different concentrations of PPD exposed to 4 J/cm<sup>2</sup>. The percentage of viable cells was calculated relative to cells not treated with PPD (darkness and UVA control). The results are expressed as the mean  $\pm$  standard deviation of at least 3 replicates.



CPZ 0.5  $\mu\text{g}/\text{mL}$   
 8-MOP 0.02  $\mu\text{g}/\text{mL}$   
 BZ-F 5  $\mu\text{g}/\text{mL}$   
 PPD 10  $\mu\text{g}/\text{mL}$


## IL-6, MCP-1



CPZ 0.5 µg/mL  
 8-MOP 0.02 µg/mL  
 BZ-F 5 µg/mL  
 PPD 10 µg/mL

## MMP-1, MMP-10


# Secretion regulation of cytokines and MMPs



**Figure 5.** Signal fold expression of different cytokines and MMPs induced by different phototoxic compounds at 4J/cm<sup>2</sup> of UVA respect to CTR+UVA.

- Photoallergens seem to upregulate secretion of MMP-1, MMP-10 and downregulate IL-6, MCP-1
- Photoirritants seem to upregulate secretion of IL-6, MCP-1

## Conclusions



## POTENTIAL BIOMARKERS FOR PHOTOALLERGY

Further studies are needed (Study of intracellular production of cytokines and MPPs, quantification by ELISA, determination in RHE...)




## 4. MORE IN VITRO MODELS IN PHOTOTOXICITY





# RBC phototoxicity test



EURL ECVAM Database

- Haemolysis of erythrocyte membranes
- Oxidation of haemoglobin

## Classification of phototoxic potential

Haemolytic factor >3\*

and/or


MetHb formation\*\* (OD +IRR – OD-IRR)

= 0.05 or greater

\* HF = (concentration of 50% haemolysis - IRR/  
concentration of 50% haemolysis +IRR)


\*\* MetHb F.= (OD +IRR – OD-IRR)

# Example 1: CPZ phototoxicity



**Figure 6. Photohaemolysis results of CPZ.** Haemolysis induced by CPZ under UVA and dark conditions.

<b>HC50 Dark</b>	459.1 µg/mL
<b>HC50 UVA</b>	110.2 µg/mL
<b>HF</b>	4.17




**Figure 7. Haemoglobin oxidation by CPZ.** Results are expressed as mean ± standard deviation of n=2. Significant haemoglobin oxidation when values of ABS are >0.05.

Photohaemolysis ✓  
 Haemoglobin oxidation ✓


**CPZ PHOTOTOXIC**

## Example 2: BIT phototoxicity



**Figure 8. Photohaemolysis results of BIT.** Haemolysis induced by BIT under UVA and dark conditions.

**HC50 Dark** 18.93µg/mL  
**HC50 UVA** 13.03 µg/mL  
**HF** 0.69



**Figure 9. Haemoglobin oxidation by BIT.** Results are expressed as mean ± standard deviation of n=2. Significant haemoglobin oxidation when values of ABS are >0.05.

Photohaemolysis ✗  
 Haemoglobin oxidation ✓

**BIT PHOTOTOXIC**

Bithionol (BIT)


### Example 3: Phototoxicity study of Guarana encapsulated




*Paullinia cupana*



**Guarana**



# Guarana encapsulated: protection of phototoxicity induced by CPZ?




**Figure 10. Photoprotective activity from free guarana and nanosomes with or without guarana.** Results are expressed as mean ± standard error of n=3. The data indicated that both free and encapsulated guarana do not induce haemolysis when irradiated (5J/cm<sup>2</sup>) and protect from photohaemolysis induced by CPZ.

FG: Free guarana


WL: White nanosome

LG: Nanosome with guarana encapsulated



**Figure 11. Protection of haemoglobin oxidation induced by CPZ with UVA.** Results are expressed as mean ± standard error of n=3. The invitro algorithm, which is an indirect measure of metahaemoglobin production, indicates significant haemoglobin oxidation when values of ABS are >0.05.

# TG No. 498 In vitro Phototoxicity: RHE phototoxicity test method



SkinEthic RHE (Episkin.com)

- Reconstituted Human Epidermis (RHE)
- Application of chemical or formulation (water/PBS, oil) overnight
- UVA Irradiation dose approx 6 J/cm<sup>2</sup>
- Redness, inflammation, cellular viability evaluation

**Table 1. Proficiency Substances<sup>1</sup>**

Substance	CAS RN	In vivo <sup>2</sup>	Vehicle <sup>3</sup>	Typical phototoxicity ranges [% w/v or % v/v] (references)
<b>PHOTOTOXIC SUBSTANCES</b>				
1 Chlorpromazine	69-09-0	PT	Water	0.003% – 0.01% (4)
2 Anthracene	120-12-7	PT	EtOH <sup>4</sup> or Acetone: Olive Oil (4:1)	0.01% – 0.03% (5)(30)
3 Bergamot oil <sup>6</sup>	8007-75-8	PT	Oil <sup>5</sup>	0.0316% – 3.16% (4)(8)
<b>NON-PHOTOTOXIC SUBSTANCES</b>				
4 Sodium Dodecyl Sulphate	151-21-3	NPT	Water	Non-phototoxic up to highest conc. tested (1%) (4)
5 Octyl salicylate	118-60-5	NPT	Oil <sup>5</sup>	Non-phototoxic up to highest conc. tested (10%) (4)
6 4- Aminobenzoic acid (PABA)	150-13-0	NPT	Oil or EtOH	Non-phototoxic up to highest con. Tested (10%).(27)(30)

# TAKE HOME MESSAGE

- Development of *In vitro* models is necessary (Cosmetic Industry,...)
- *In vitro* models to discriminate photoallergens are not available
- New methods addressed to KE of AOP are under development
- Protocols and official guides available in database for phototoxicity



# ACKNOWLEDGMENT

## Cellular Response to Xenobiotics (CEREX)

## Research group in toxicology (GRET)




Dra. Montse Mitjans




Dra. M. Pilar Vinardell



Dra. Elisabet Teixidó



Dra. Adriana S. Maddaleno




Ramon Romero



Natalia Gala Martínez



Ruth Torregrosa



Eloi Reig



Project PID2020-113186RB-I00 funded by  
MCIN/AEI/10.13039/501100011033



# ***IN VITRO* MODELS TO PREDICT PHOTOTOXICITY: STRATEGIES BASED ON THE CELLULAR MECHANISMS INVOLVED**

Dra. Adriana S. Maddaleno

Secció Fisiologia

Facultat de Farmàcia i CCAA

Seminari de recerca 10/04/24



UNIVERSITAT DE  
BARCELONA

Facultat de Farmàcia  
i Ciències de l'Alimentació